Home・Elenco Azioni・Glaukos Corp

Glaukos Corp

Chiusa

SettoreSettore sanitario

189.3 3.13

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

182.37

Massimo

185.8

Metriche Chiave
By Trading Economics
Entrata	1.4M -18M
Vendite	35M 186M
EPS	-0.14
Margine di Profitto	-9.901
Dipendenti	1,094
EBITDA	-1.6M -6.9M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+2.24% upside

Dividendi
By Acuity
Utili prossimi	28 ott 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	2B 11B
Apertura precedente	186.17
Chiusura precedente	189.3

Notizie sul Sentiment di mercato

By Acuity

43%

57%

142 / 340 Classifica in Healthcare

Glaukos Corp Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

14 ago 2026, 19:46 UTC

Glaukos Corp. shares are lower today, reaching a session low amid broader market declines following a surprise drop in U.S. retail sales for July.

13 ago 2026, 19:22 UTC

Glaukos Corp. shares are higher today amid unusually high trading volume. The stock remains significantly above its 20-day moving average.

12 ago 2026, 19:16 UTC

Glaukos Corp shares are higher today, supported by overall strength in U.S. stocks and positive quarterly results from AI sector companies.

10 ago 2026, 20:06 UTC

Glaukos Corp shares are higher today, following a broader market trend since Friday. Earlier, the stock reached a session high before pulling back.

7 ago 2026, 20:02 UTC

Glaukos Corp shares are rising in Friday's session, supported by unusually high trading volume and a steady upward trend since Thursday's close.

4 ago 2026, 19:36 UTC

Glaukos Corp shares are lower today, impacted by declines in the Health Care Equipment sub-sector. The stock pulled back after reaching an earlier high.

3 ago 2026, 20:06 UTC

Glaukos Corp shares are higher amid positive market sentiment, with the S&P 500 and Nasdaq 100 also gaining. The stock remains above its 20-day moving average.

31 lug 2026, 19:45 UTC

News

Glaukos shares are lower today despite H.C. Wainwright raising the price target to $195 from $168. Trading volume has been unusually high.

30 lug 2026, 21:31 UTC

News

Glaukos Corp shares are lower in after-market trading, tracking declines in the Health Care Equipment sector. UBS raised its price target to $172.

29 lug 2026, 21:22 UTC

Social Media

News

Glaukos Corp reported record net sales of $185.6 million in Q2 2026, raising its full-year revenue guidance to $680 million to $700 million. Shares are higher in after-market trading.

28 lug 2026, 17:46 UTC

News

Glaukos Corp shares are lower after UBS initiated coverage with a Neutral rating, overshadowing Stifel's Buy rating and $175 price target.

27 lug 2026, 19:16 UTC

Glaukos Corp shares are lower today, despite an initial gain. Broader market trends are affected by a significant drop in oil prices.

24 lug 2026, 19:56 UTC

Glaukos Corp. shares are trading higher today, maintaining a cumulative gain since Thursday and remaining above their 20-day moving average.

21 lug 2026, 17:41 UTC

Glaukos Corp shares are lower today amid a decline in the Health Care Equipment sub-sector, reversing the recent trend of higher daily closes.

Confronto tra pari

Modifica del prezzo

Glaukos Corp Previsione

Obiettivo di Prezzo

By TipRanks

2.24% in crescita

Previsioni per 12 mesi

Media 189.77 USD 2.24%

Alto 225 USD

Basso 153 USD

Basato su 14 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Glaukos Corp - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

14 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 14 che hanno fornito valutazioni azionarie a Glaukos Corp - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

142 / 340 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Glaukos Corp

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.